We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
-2.45%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$364M
AUM Growth
-$19.7M
Cap. Flow
-$6.77M
Cap. Flow %
-1.86%
Top 10 Hldgs %
44.42%
Holding
83
New
22
Increased
23
Reduced
12
Closed
26

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$17.9M
2
ICLR icon
Icon
ICLR
+$17.1M
3
TMO icon
Thermo Fisher Scientific
TMO
+$14M
4
THC icon
Tenet Healthcare
THC
+$13.5M
5
RCM
R1 RCM Inc. Common Stock
RCM
+$10.6M

Top Sells

Rank Stock Value
1
KIDS icon
OrthoPediatrics
KIDS
+$19.3M
2
AHCO icon
AdaptHealth
AHCO
+$14.7M
3
SNY icon
Sanofi
SNY
+$13.5M
4
BDX icon
Becton Dickinson
BDX
+$13.2M
5
CVS icon
CVS Health
CVS
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 80.17%
2 Industrials 3.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JNJ icon
26
Johnson & Johnson
JNJ
$618B
$5.44M 1.49%
32,998
+4,144
+14% +$686K
AVTR icon
27
Avantor
AVTR
$9.32B
$5.41M 1.49%
152,395
-88,621
-37% -$2.87M
COR icon
28
Cencora
COR
$60.6B
$4.78M 1.31%
41,729
-20,993
-33% -$2.48M
ELV icon
29
Elevance Health
ELV
$81.5B
$4.56M 1.25%
11,941
-19,857
-62% -$7.59M
FATE icon
30
Fate Therapeutics
FATE
$286M
$4.43M 1.22%
51,031
+37,599
+280% +$3.03M
SPRY icon
31
ARS Pharmaceuticals
SPRY
$509M
$4.3M 1.18%
+139,124
New +$4.46M
CALT
32
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$4.25M 1.17%
144,393
+2,070
+1% +$59.2K
IOVA icon
33
Iovance Biotherapeutics
IOVA
$1.82B
$4.17M 1.15%
160,362
-150,287
-48% -$3.91M
RNAC icon
34
Cartesian Therapeutics
RNAC
$229M
$3.88M 1.07%
30,898
+508
+2% +$60.5K
PRAX icon
35
Praxis Precision Medicines
PRAX
$8.58B
$3.65M 1%
+13,304
New +$4.76M
ALBO
36
DELISTED
Albireo Pharma Inc
ALBO
$3.64M 1%
103,512
+337
+0.3% +$11K
MDVL
37
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$3.58M 0.98%
5,844
+1,249
+27% +$815K
REGN icon
38
Regeneron Pharmaceuticals
REGN
$78.5B
$3.11M 0.85%
+5,563
New +$2.82M
TFX icon
39
Teleflex
TFX
$6.05B
$3.01M 0.83%
+7,501
New +$3.07M
ACH
40
Accendra Health
ACH
$237M
$2.84M 0.78%
66,989
+2,977
+5% +$116K
MREO
41
Mereo BioPharma
MREO
$54.7M
$2.4M 0.66%
756,915
-582,920
-44% -$1.96M
SRPT icon
42
Sarepta Therapeutics
SRPT
$1.57B
$2.23M 0.61%
+28,625
New +$2.17M
IMUX icon
43
Immunic
IMUX
$190M
$2.17M 0.6%
17,715
+4,535
+34% +$627K
RGLS
44
DELISTED
Regulus Therapeutics
RGLS
$2.12M 0.58%
260,767
+23,111
+10% +$258K
ACRS icon
45
Aclaris Therapeutics
ACRS
$726M
$2.1M 0.58%
119,378
-336,007
-74% -$7.63M
BAX icon
46
Baxter International
BAX
$13.5B
$2.02M 0.55%
+25,059
New +$2.1M
PNTG icon
47
Pennant Group
PNTG
$1.4B
$1.94M 0.53%
+47,475
New +$1.85M
FBRX icon
48
Forte Biosciences
FBRX
$1.57B
$1.79M 0.49%
2,135
+1,031
+93% +$929K
VRTX icon
49
Vertex Pharmaceuticals
VRTX
$121B
$1.52M 0.42%
+7,553
New +$1.58M
SIBN icon
50
SI-BONE Inc
SIBN
$788M
$1.26M 0.35%
+40,155
New +$1.3M
1
2
3 4

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Endurant Capital Management held 83 positions worth $364M, down 5.1% from $384M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Endurant Capital Management's Q2 2021 filing shows 22 new, 23 increased, 12 reduced and 26 closed positions. Its largest new stake was Cigna: 71,856 shares worth $17M. The largest sale was OrthoPediatrics, an estimated $19.3M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 86% a quarter earlier, followed by Industrials.

  • Endurant Capital Management's largest Q2 2021 buy was Cigna: 71,856 shares worth $17M.
  • Endurant Capital Management added most to R1 RCM Inc. Common Stock in Q2 2021, an estimated $10.6M increase.
  • Endurant Capital Management's biggest Q2 2021 reduction was Bristol-Myers Squibb, cutting an estimated $8.66M.
  • Endurant Capital Management fully exited OrthoPediatrics in Q2 2021, selling an estimated $19.3M.
  • Endurant Capital Management's ten largest holdings make up 44% of its $364M portfolio in Q2 2021.
  • Endurant Capital Management opened 22 new positions and closed 26 in Q2 2021.
  • Endurant Capital Management's portfolio value fell 5.1% quarter-over-quarter to $364M.

Based on Endurant Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.